3 Problems Doctors Face When Prescribing Medical Marijuana

By Admin
Medical marijuana has been a controversial topic amongst physicians for decades, but with more and more states legalizing the therapeutic drug doctors n...

Medical marijuana has been a controversial topic amongst physicians for decades, but with more and more states legalizing the therapeutic drug doctors need to inform themselves if prescribing cannabis is the right thing to do.

Ziva D. Cooper, PhD, Assistant Professor of Clinical Neurology at Columbia University, is intrigued by the enduring power of psychoactive substances to maintain drug-taking behavior. She believes there are three major limitations doctors face when prescribing medical marijuana and shared her insight on The Doctors Channel.

Dr. Cooper explained that a lack of controlled studies and unknown risks to pulmonary health are the main concerns for many doctors.

Here are the three problems doctors face when prescribing medical marijuana.

Problem 1: There have not been double blind, placebo controlled studies demonstrating the efficacy of marijuana for the number of indications for which it is prescribed.

“To take it one step further, there also haven’t been studies to determine that marijuana is better than some of the other medications that are on the market,” said Cooper. “So this is an important consideration when deciding to prescribe a patient medical marijuana.”

Problem 2: There are risks to using medical marijuana including dependence and the fact that smoking anything will compromise pulmonary health.

“If somebody is opting for the medical marijuana route, some things to consider would be, let’s say, vaporizing,” Cooper said. “Whenever somebody smokes anything, there’s this carbon monoxide expiration and this is an indication that it’s not necessarily a good thing to do. When somebody vaporizes, the carbon monoxide levels are negligible.”

Problem 3: Marijuana is not necessarily controlled and studied in terms of the different chemicals that are in it.

“Different strains have different names and actually now there are services that are provided that can use methods to detect how much THC is in each strain [and] how much cannabidiol is in each strain,” Cooper added. “But when a patient goes to a medical dispensary, they might not necessarily know all the other components that are in there or how much THC is in that strain.”   

Share

Featured Articles

Global Health Funding 'Facing Post-Pandemic Challenges'

IHME report highlights shifting priorities and economic pressures affecting global health financing, despite increase in funding since pre-COVID levels

The Merck Group: Pharma's History & Innovation in India

Welcome back to part two of our exploration of The Merck Group's history and investment in China and India, with this part focusing on innovation in India

How CVS Health is Rising to the Omnichannel Challenge

US healthcare company CVS Health is reshaping its supply chain to meet the omnichannel needs of its customers

Kinaxis: Pharma Seeing Euro-wide Supply Chain Challenges

Procurement & Supply Chain

Healthcare Digital Transformations Stymied by Data Silos

Digital Healthcare

McKinsey: Brain Health Underfunding 'a Global Concern'

Digital Healthcare